U.S. markets open in 4 hours 14 minutes

CNS Pharmaceuticals, Inc. (CNSP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0200+0.1000 (+5.21%)
At close: 4:00PM EST

1.9500 -0.07 (-3.47%)
Before hours: 4:48AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close1.9200
Open1.8800
Bid0.0000 x 1200
Ask0.0000 x 1000
Day's Range1.9100 - 2.0400
52 Week Range1.2580 - 5.6200
Volume2,776,773
Avg. Volume1,340,038
Market Cap48.19M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6370
Earnings DateMar 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
    GlobeNewswire

    InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco

    LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), was recently interviewed on the C3 Chat Show Podcast, a series that addresses topics related to entrepreneurship, life experiences and best practices from experts. The podcast, co-hosted by Sid Vaidya and Eric Gershey, is available for on-demand listening at https://anchor.fm/c3chat.During the interview, Climaco provided an overview of CNS Pharmaceuticals and recent FDA approval to begin clinical trials on the company’s lead drug candidate, Berubicin, a proposed treatment for glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.“This is the biggest news we’ve announced since our IPO back in November 2019. The FDA approved an Investigational New Drug application, which allows us to proceed with our clinical trial. Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials for our lead compound, Berubicin, which is a novel treatment for glioblastoma, the most common and aggressive form of primary brain cancer,” Climaco said.“We have five employees at this company, so we are a tiny little shop,” he continued. “But we have an absolute powerhouse compound. We pushed that through and got the FDA to greenlight a clinical trial, which is really monumental. The Food and Drug Administration of the United States said it’s safe to proceed and investigate this drug in humans.”“It’s a big day for GBM patients. This is a population that has not seen hardly any innovation for 15 years,” he said. “If you get GBM, the sad reality is you’re probably going to die from it. We think we can change that game.”“We expect to be enrolling patients as soon as January or February. We know how this drug behaves. It was the subject of a very successful Phase I trial where 44 percent of patients had their disease stabilized or they started to get better. Those are remarkable statistics, because GBM is the deadliest form of brain cancer. Basically no one gets better. But we have a patient who is still alive 14 years after treatment, and that’s just incredible because the median survival for GBM patients following diagnosis is 14-16 months.”Throughout the podcast, Climaco discussed the difficulties in treating brain cancers because of the brain’s protective covering of specialized cells that shield it from outside infection. He also explained how Berubicin is able to cross the blood-brain barrier and attack tumor cells inside the brain.Learn more by listening to the full interview at https://anchor.fm/c3chat.About CNS Pharmaceuticals Inc.CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.For more information, visit: www.cnspharma.comAbout InvestorBrandNetworkThe InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.For more information on IBN, visit https://www.InvestorBrandNetwork.com.Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: https://IBN.fm/DisclaimerForward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.Corporate CommunicationsInvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

  • CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference
    PR Newswire

    CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.

  • CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
    GlobeNewswire

    CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

    HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ recent announcement that the Investigational New Drug (IND) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM) is now approved and in effect as filed with the US Food and Drug Administration (FDA). To hear the audio production, visit: https://www.nnw.fm/WCRwHTo read the original press release, visit: https://nnw.fm/zWHqI"Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year," commented John Climaco, CEO of CNS Pharmaceuticals. "The Company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase 2 trial in the U.S., and 2 trials planned by our sublicensee WPD in Poland. We are entering an area with significant unmet medical need since the current treatment paradigm for GBM remains bleak, as this aggressive and currently incurable form of brain cancer continues to claim high mortality rates. We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial."Last week, CNS Pharmaceuticals hosted a virtual presentation to discuss the FDA IND approval and planned Phase 2 Berubicin clinical trial. To view the recorded webinar, visit https://edge.media-server.com/mmc/p/rg8hxqpbAbout CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of the first quarter of 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.For more information, visit: www.cnspharma.comAbout NetworkNewsAudioNetworkNewsAudio (“NNA”), one of 50+ brands within the InvestorBrandNetwork (“IBN”), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.For more information, visit: www.NetworkNewsAudio.comPlease see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/DisclaimerForward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Company and WPD to initiate clinical trials during the first quarter of 2021, and whether the planned clinical trial will provide data to the FDA to allow an expedited pathway for development. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.Corporate Communications: InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com